Circulation. 2003;107:517-520
Published online before print January 20, 2003, doi: 10.1161/01.CIR.0000054163.42072.D4
Published online before print January 20, 2003, doi: 10.1161/01.CIR.0000054163.42072.D4
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:517.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries
A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT)
From the Department of Medicine, University of Ulsan College of Medicine, Seoul, Korea (M.-K.H., C.W.L., J.-M.S., K.-H.H., D.-H.K., J.-K.S., J.-J.K., S.-W.P., S.-J.P.); Cardiovascular Research Foundation, New York, NY (G.S.M.); Washington Hospital Center, Washington, DC (N.J.W.); and MED Institute, Inc, West Lafayette, Ind (N.E.F.).
Correspondence to Seung-Jung Park, MD, Departments of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul, 138-736, Korea. E-mail sjpark{at}amc.seoul.kr
Background— The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effect of a paclitaxel coating on in-stent intimal hyperplasia (IH).
Methods and Results— Patients were randomized to placebo (bare metal stents) or 1 of 2 doses of paclitaxel (low dose: 1.28 µg/mm2; high dose: 3.10 µg/mm2). Complete post-stent implantation and follow-up IVUS were available in 81 patients, including 25 control patients and in 28 receiving a low-dose and 28 receiving a high dose. Volumetric analysis of the stented segment and of both reference segments was performed. Baseline stent measurements and both reference measurements were similar among the groups. With increasing doses, there was a stepwise reduction in IH accumulation within the stented segment (31±22 mm3 in control, 18±15 mm3 in low dose, and 13±14 mm3 in high dose, P<0.001). Post hoc analysis showed less IH accumulation when low- and high-dose patients were compared with control (P=0.009 and P<0.001, respectively), but not when low-dose patients were compared with high-dose patients (P=0.2). Focal late malapposition was seen in 1 high-dose patient. With increasing doses, there was no significant change in the reference segments.
Conclusions— Paclitaxel-coated stents are effective in reducing in-stent neointimal tissue proliferation in humans. They are not associated with edge restenosis or significant late malapposition.
Key Words: stents • restenosis • ultrasonics
This article has been cited by other articles:
 |
|
 |
|
  H. S. Hecht, S. Polena, V. Jelnin, M. Jimenez, T. Bhatti, M. Parikh, G. Panagopoulos, and G. Roubin Stent gap by 64-detector computed tomographic angiography relationship to in-stent restenosis, fracture, and overlap failure. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1949 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Higo, Y. Ueda, J. Oyabu, K. Okada, M. Nishio, A. Hirata, K. Kashiwase, N. Ogasawara, S. Hirotani, and K. Kodama Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent an angioscopic study. J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 616 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K.M. Hassan, S. C. Bergheanu, T. Stijnen, B. L. van der Hoeven, J. D. Snoep, J. W.M. Plevier, M. J. Schalij, and J. W. Jukema Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis Eur. Heart J., January 21, 2009; (2009) ehn553v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Chen, L. V. Crisco, R. Jabara, and S. B. King III Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents? Angiology, January 1, 2009; 59(6): 667 - 675. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G Raja and G. D Dreyfus Current Status of Off-pump Coronary Artery Bypass Surgery Asian Cardiovasc Thorac Ann, April 1, 2008; 16(2): 164 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Godet, Y. Le Manach, F. Lesache, S. Perbet, and P. Coriat Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem? Br. J. Anaesth., April 1, 2008; 100(4): 472 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Weissman, S. G. Ellis, E. Grube, K. D. Dawkins, J. D. Greenberg, T. Mann, L. A. Cannon, P. A. Cambier, S. Fernandez, G. S. Mintz, et al. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials Eur. Heart J., July 1, 2007; 28(13): 1574 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Elezi, A. Dibra, J. Mehilli, J. Pache, R. Wessely, A. Schomig, and A. Kastrati Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement: Results From a Large Cohort of Patients Treated With Sirolimus- or Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1304 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Lee, H.-C. Tan, and Y.-T. Lim Update on Drug-Eluting Stents for Prevention of Restenosis Asian Cardiovasc Thorac Ann, February 1, 2006; 14(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K D Dawkins, T Gershlick, M de Belder, A Chauhan, G Venn, P Schofield, D Smith, J Watkins, H H Gray, and Joint Working Group on Percutaneous Coronary Inter Percutaneous coronary intervention: recommendations for good practice and training Heart, December 1, 2005; 91(suppl_6): vi1 - vi27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Nawarskas and L. A. Osborn Paclitaxel-eluting stents in coronary artery disease Am. J. Health Syst. Pharm., November 1, 2005; 62(21): 2241 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ako, Y. Morino, Y. Honda, A. Hassan, S. Sonoda, P. G. Yock, M. B. Leon, J. W. Moses, H. N. Bonneau, and P. J. Fitzgerald Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation: A Serial Intravascular Ultrasound Analysis J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1002 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hausleiter, A. Kastrati, R. Wessely, A. Dibra, J. Mehilli, T. Schratzenstaller, I. Graf, M. Renke-Gluszko, B. Behnisch, J. Dirschinger, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating Eur. Heart J., August 1, 2005; 26(15): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, G. Sianos, A. Abizaid, J. Aoki, P. den Heijer, H. Bonnier, P. Smits, D. McClean, S. Verheye, J. Belardi, et al. The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform: The Paclitaxel In-Stent Controlled Elution Study (PISCES) J. Am. Coll. Cardiol., July 19, 2005; 46(2): 253 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Balakrishnan, A. R. Tzafriri, P. Seifert, A. Groothuis, C. Rogers, and E. R. Edelman Strut Position, Blood Flow, and Drug Deposition: Implications for Single and Overlapping Drug-Eluting Stents Circulation, June 7, 2005; 111(22): 2958 - 2965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A H Gershlick Drug eluting stents in 2005 Heart, June 1, 2005; 91(suppl_3): iii24 - iii31. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Weissman, J. Koglin, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1201 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Moreno, C. Fernandez, R. Hernandez, F. Alfonso, D. J. Angiolillo, M. Sabate, J. Escaned, C. Banuelos, A. Fernandez-Ortiz, and C. Macaya Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies J. Am. Coll. Cardiol., March 15, 2005; 45(6): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanabe, P. W. Serruys, M. Degertekin, E. Grube, G. Guagliumi, W. Urbaszek, J. Bonnier, J.-M. Lablanche, T. Siminiak, J. Nordrehaug, et al. Incomplete Stent Apposition After Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights From the Randomized TAXUS II Trial Circulation, February 22, 2005; 111(7): 900 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Sindermann, V. Verin, J. W Hopewell, H. P. Rodemann, and J. H Hendry Biological aspects of radiation and drug-eluting stents for the prevention of restenosis Cardiovasc Res, July 1, 2004; 63(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H Chong and J. W. Cheng Early Experiences and Clinical Implications of Restenosis and Drug-Eluting Stents: Part 2 Ann. Pharmacother., May 1, 2004; 38(5): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Orford, A. Lerman, and D. R. Holmes Routine intravascular ultrasound guidance of percutaneous coronary intervention: A critical reappraisal J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill and S. R. Dixon The year in interventional cardiology J. Am. Coll. Cardiol., March 3, 2004; 43(5): 875 - 890. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Chaves, A. G.M.R. Sousa, L. A. Mattos, A. Abizaid, R. Staico, F. Feres, M. Centemero, L. F. Tanajura, A. Abizaid, I. Pinto, et al. Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial Circulation, February 24, 2004; 109(7): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, M. Degertekin, K. Tanabe, M. E. Russell, G. Guagliumi, J. Webb, J. Hamburger, W. Rutsch, C. Kaiser, R. Whitbourn, et al. Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial Circulation, February 10, 2004; 109(5): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gershlick, I. De Scheerder, B. Chevalier, A. Stephens-Lloyd, E. Camenzind, C. Vrints, N. Reifart, L. Missault, J.-J. Goy, J. A. Brinker, et al. Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial Circulation, February 3, 2004; 109(4): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sindermann, G. Plenz, and G. Breithardt Drug-Eluting Stents: Do We Know Enough About Safety? Circulation, January 27, 2004; 109 (3): e22 - e22. [Full Text] [PDF]
|
|
|
|
|
|
K. Tanabe, P. W. Serruys, M. Degertekin, G. Guagliumi, E. Grube, C. Chan, T. Munzel, J. Belardi, W. Ruzyllo, L. Bilodeau, et al. Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II Trial Circulation, January 20, 2004; 109(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Taylor and C. A. McNamara Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1717 - 1720. [Full Text] [PDF]
|
|
|
|
|
|
G. S. Mintz, A. Tinana, M.-K. Hong, C. W. Lee, J.-J. Kim, N. E. Fearnot, S.-W. Park, S.-J. Park, and N. J. Weissman Impact of Preinterventional Arterial Remodeling on Neointimal Hyperplasia After Implantation of (Non-Polymer-Encapsulated) Paclitaxel-Coated Stents: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) Circulation, September 16, 2003; 108(11): 1295 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Curfman, S. Morrissey, and J. M. Drazen Notice of Duplicate Publication N. Engl. J. Med., May 29, 2003; 348(22): 2254 - 2254. [Full Text] [PDF]
|
|